Global Osteosarcoma News

From the National Cancer Institute

• Combination immunotherapy shrank a variety of metastatic solid cancers
  A new form of personalized cancer immunotherapy, known as tumor infiltrating lymphocyte (TIL) therapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers.
• Daily physical activity, even at light intensities, linked to lower cancer risk
  A study of 85,000 older adults in the U.K. suggests that light- and moderate-to-vigorous-intensity daily physical activity can reduce cancer risk. The number of steps taken daily may be more important for cancer risk than the intensity of activity, the study shows.
• Gene therapy shows clinical benefit in patients with a debilitating disorder caused by HPV
  An NCI clinical trial showed that an experimental gene therapy called PRGN-2012 may be an effective treatment for recurrent respiratory papillomatosis, which is caused by HPV 6 and HPV 11.
• In five cancer types, prevention and screening have been major contributors to saving lives
  Over the past 45 years, the majority of deaths averted from breast, cervical, colorectal, lung, and prostate cancer were due to prevention and screening, rather than treatment advances, NCI researchers have found.
• Researchers uncover new role of mutant RAS proteins in some of the deadliest cancers
  A new study led by NCI researchers shows that mutant RAS proteins help release a nuclear protein from a complex transported from the nucleus to the cytoplasm, kicking off a series of events that lead to the breakdown of a tumor suppressor protein.
• NIH-funded scientists uncover clues to precancer and tumor biology
  New studies released by NCI’s Human Tumor Atlas Network explore the role of the tumor microenvironment and the immune system in promoting the spread of cancer and its resistance to treatment. The studies appear across several Nature journals.
• NIH clinical trial will test precision medicine treatments for myeloid cancers
  NCI has launched myeloMATCH, a precision medicine treatment trial that will test treatment combinations targeting specific genetic changes in people with acute myeloid leukemia and myelodysplastic syndromes.
• New cancer diagnoses did not rebound as expected following pandemic
  While new cancer diagnoses largely returned to pre-pandemic levels in 2021, they don’t account for the missed diagnoses in early 2020 that resulted from disruptions in cancer screening and other medical care.